Omega Therapeutics (OMGA) Stock Price, News & Analysis

Company Overview

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.76 to $0.81
• 50-Day Range: $0.76 to $1.45
• 52-Week Range: $0.75 to $6.30
• Volume: 221,464 shs
• Average Volume: 865,326 shs
• Market Capitalization: $43.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.20
• Consensus Rating: Moderate Buy

Omega Therapeutics Stock Analysis - MarketRank™

Omega Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 745th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omega Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Omega Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Omega Therapeutics are expected to grow in the coming year, from ($1.18) to ($0.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omega Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omega Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Omega Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

31.10% of the float of Omega Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Omega Therapeutics has a short interest ratio ("days to cover") of 26.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Omega Therapeutics has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omega Therapeutics does not currently pay a dividend.

Dividend Growth

Omega Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

31.10% of the float of Omega Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Omega Therapeutics has a short interest ratio ("days to cover") of 26.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Omega Therapeutics has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.34

News Sentiment

Omega Therapeutics has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Omega Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for OMGA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Omega Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Omega Therapeutics is held by insiders.

Percentage Held by Institutions

97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMGA Stock Analysis - Frequently Asked Questions

How have OMGA shares performed this year?

Omega Therapeutics' stock was trading at $3.01 on January 1st, 2024. Since then, OMGA shares have decreased by 73.7% and is now trading at $0.7902.
View the best growth stocks for 2024 here.

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics, Inc. (NASDAQ:OMGA) posted its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm earned $2.13 million during the quarter, compared to analyst estimates of $1.25 million. Omega Therapeutics had a negative trailing twelve-month return on equity of 213.13% and a negative net margin of 902.93%.

When did Omega Therapeutics IPO?

Omega Therapeutics (OMGA) raised $126 million in an initial public offering on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share.

Who are Omega Therapeutics' major shareholders?

Omega Therapeutics' top institutional shareholders include FMR LLC (10.99%), Green Alpha Advisors LLC (0.11%) and XTX Topco Ltd (0.06%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young.
View institutional ownership trends.

How do I buy shares of Omega Therapeutics?

Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Omega Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Omega Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OMGA
• CUSIP: N/A
• CIK: 1850838
• Web: www.omegatherapeutics.com
• Phone: 617-949-4360
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.20
• High Stock Price Target: $12.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +1,064.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-97,430,000.00
• Net Margins: -902.93%
• Pretax Margin: -902.93%
• Return on Equity: -213.13%
• Return on Assets: -41.24%

Debt

• Debt-to-Equity Ratio: 1.00
• Current Ratio: 1.61
• Quick Ratio: 1.61

Sales & Book Value

• Annual Sales: $8.10 million
• Price / Sales: 5.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 55,366,000
• Free Float: 50,660,000
• Market Cap: $43.75 million
• Optionable: Optionable
• Beta: 1.84